NASDAQ:SLGL

Sol-Gel Technologies Stock Forecast, Price & News

$14.70

+1.30 (+9.70 %)

(As of 04/15/2021 12:00 AM ET)

Add

Compare

Today's Range

$13.41

Now: $14.70▼

$15.23

50-Day Range

$8.75

MA: $11.51▼

$15.49

52-Week Range

$7.00

Now: $14.70▼

$16.69

Volume140,059 shs

Average Volume53,413 shs

Market Capitalization$299.73 million

P/E RatioN/A

Dividend YieldN/A

Beta1.36

Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions. It is also involved in the development of generic topical dermatological drug products. Sol-Gel Technologies Ltd. has collaboration with Perrigo. The company was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:SLGL

Previous Symbol

CUSIPN/A

CIK1684693

Webwww.sol-gel.com

Phone972-8931-3429

Employees65

Year FoundedN/A

Debt

Debt-to-Equity RatioN/A

Current Ratio8.55

Quick Ratio8.55

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$22.90 million

Price / Sales13.09

Cash FlowN/A

Price / Cash FlowN/A

Book Value$2.57 per share

Price / Book5.72

Profitability

EPS (Most Recent Fiscal Year)($1.26)

Net Income$-24,610,000.00

Net Margins-273.92%

Return on Equity-48.54%

Return on Assets-42.14%

Miscellaneous

Outstanding Shares20,390,000

Market Cap$299.73 million

Next Earnings Date5/13/2021 (Estimated)

OptionableNot Optionable

Headlines

Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Expected to Announce Quarterly Sales of $1.72 Million
April 13, 2021 | americanbankingnews.com

Zacks: Brokerages Anticipate Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Will Announce Earnings of -$0.49 Per Share
April 11, 2021 | americanbankingnews.com

Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Expected to Post Quarterly Sales of $1.72 Million
March 27, 2021 | americanbankingnews.com

Sol-Gel Technologies (NASDAQ:SLGL) Is In A Good Position To Deliver On Growth Plans
March 19, 2021 | finance.yahoo.com

Sol-Gel Technologies Reports Full Year 2020 Financial Results and Corporate Update
March 4, 2021 | finance.yahoo.com

Sol-Gel Technologies to Present at Upcoming 2021 Raymond James Institutional Investors Conference and H.C. Wainwright Global Life Sciences Conference
February 24, 2021 | finance.yahoo.com

Have Insiders Been Buying Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Shares?
January 19, 2021 | finance.yahoo.com

Sol-Gel Technologies Announces FDA Acceptance for Filing of New Drug Application for Twyneo(R) for the Treatment of Acne Vulgaris
December 7, 2020 | marketwatch.com

What You Need To Know About The Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Analyst Downgrade Today
November 18, 2020 | finance.yahoo.com

Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Just Reported And Analysts Have Been Cutting Their Estimates
November 16, 2020 | finance.yahoo.com

Recap: Sol-Gel Technologies Q3 Earnings
November 12, 2020 | finance.yahoo.com

Sol-Gel Technologies Reports Third Quarter 2020 Financial Results and Corporate Update
November 12, 2020 | markets.businessinsider.com

Sol-Gel Technologies EPS beats by $0.09, beats on revenue
November 12, 2020 | seekingalpha.com

Sol-Gel to Present at Upcoming Healthcare Investor Conferences in November 2020
November 9, 2020 | finance.yahoo.com

Sol-Gel Technologies Ltd. Ordinary Shares (SLGL)
November 5, 2020 | nasdaq.com

Sol-Gel Technologies to Report Third Quarter 2020 Financial Results on November 12, 2020
November 4, 2020 | finance.yahoo.com

FDA accepts Sol-Gel application for rosacea cream
September 10, 2020 | seekingalpha.com

Sol-Gel jumps on FDA acceptance of Epsolay NDA
September 10, 2020 | seekingalpha.com

Sol-Gel Technologies Announces FDA Acceptance for Filing of New Drug Application for Epsolay® for the Treatment of Inflammatory Lesions of Rosacea
September 10, 2020 | finance.yahoo.com

Sol-Gel to Present at Upcoming Healthcare Investor Conferences in September
September 8, 2020 | finance.yahoo.com

See More Headlines

MarketRank^™

Overall MarketRank^™

1.16 out of 5 stars

Medical Sector

949th out of 2,021 stocks

Pharmaceutical Preparations Industry

447th out of 772 stocks

3.5 Analyst's Opinion

Consensus Rating
Sol-Gel Technologies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $21.00, Sol-Gel Technologies has a forecasted upside of 42.9% from its current price of $14.70.
Amount of Analyst Coverage
Sol-Gel Technologies has received no research coverage in the past 90 days.

2.3 Community Rank

Outperform Votes
Sol-Gel Technologies has received 128 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Sol-Gel Technologies has received 147 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Sol-Gel Technologies has received 53.45% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Sol-Gel Technologies and other stocks. Vote “Outperform” if you believe SLGL will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SLGL will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Sol-Gel Technologies does not currently pay a dividend.
Dividend Growth
Sol-Gel Technologies does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Sol-Gel Technologies insiders have not sold or bought any company stock.
Percentage Held by Institutions
Only 30.88% of the stock of Sol-Gel Technologies is held by institutions.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Sol-Gel Technologies are expected to decrease in the coming year, from ($1.43) to ($2.06) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Sol-Gel Technologies is -11.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Sol-Gel Technologies is -11.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Sol-Gel Technologies has a P/B Ratio of 5.72. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

$14.70

+1.30 (+9.70 %)

(As of 04/15/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive SLGL News and Ratings via Email

Sign-up to receive the latest news and ratings for SLGL and its competitors with MarketBeat's FREE daily newsletter.

Sol-Gel Technologies (NASDAQ:SLGL) Frequently Asked Questions

Is Sol-Gel Technologies a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sol-Gel Technologies in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Sol-Gel Technologies stock.
View analyst ratings for Sol-Gel Technologies or view top-rated stocks.

What stocks does MarketBeat like better than Sol-Gel Technologies?

Wall Street analysts have given Sol-Gel Technologies a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Sol-Gel Technologies wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Sol-Gel Technologies' next earnings date?

Sol-Gel Technologies is scheduled to release its next quarterly earnings announcement on Thursday, May 13th 2021.
View our earnings forecast for Sol-Gel Technologies.

How were Sol-Gel Technologies' earnings last quarter?

Sol-Gel Technologies Ltd. (NASDAQ:SLGL) issued its quarterly earnings data on Wednesday, March, 3rd. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.13. The company had revenue of ($10.11) million for the quarter, compared to analysts' expectations of $1.62 million. Sol-Gel Technologies had a negative trailing twelve-month return on equity of 48.54% and a negative net margin of 273.92%.
View Sol-Gel Technologies' earnings history.

How has Sol-Gel Technologies' stock price been impacted by COVID-19?

Sol-Gel Technologies' stock was trading at $8.25 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, SLGL stock has increased by 78.2% and is now trading at $14.70.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for SLGL?

2 brokers have issued 12 month price targets for Sol-Gel Technologies' shares. Their forecasts range from $21.00 to $21.00. On average, they expect Sol-Gel Technologies' stock price to reach $21.00 in the next twelve months. This suggests a possible upside of 42.9% from the stock's current price.
View analysts' price targets for Sol-Gel Technologies or view top-rated stocks among Wall Street analysts.

Who are Sol-Gel Technologies' key executives?

Sol-Gel Technologies' management team includes the following people:

Dr. Alon Seri-Levy, Co-Founder, CEO & Director (Age 60, Pay $397k)
Mr. Gilad Mamlok, Chief Financial Officer (Age 53, Pay $364k)
Mr. John M. Vieira, U.S. Head of Commercialization (Age 51, Pay $284k)
Prof. David Avnir, Co-Founder
Dr. Itzik Yosef, Chief Operating Officer (Age 45)
Dr. Karine Neimann, VP of Projects & Planning and Chief Chemist (Age 50)

Who are some of Sol-Gel Technologies' key competitors?

Some companies that are related to Sol-Gel Technologies include Mersana Therapeutics (MRSN), Y-mAbs Therapeutics (YMAB), Avid Bioservices (CDMO), Protagonist Therapeutics (PTGX), Phathom Pharmaceuticals (PHAT), Omeros (OMER), Kiniksa Pharmaceuticals (KNSA), Constellation Pharmaceuticals (CNST), Zogenix (ZGNX), Pliant Therapeutics (PLRX), Northwest Biotherapeutics (NWBO), MannKind (MNKD), Trillium Therapeutics (TRIL), G1 Therapeutics (GTHX) and Enanta Pharmaceuticals (ENTA).
View all of SLGL's competitors.

What other stocks do shareholders of Sol-Gel Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sol-Gel Technologies investors own include CorMedix (CRMD), NVIDIA (NVDA), Advanced Micro Devices (AMD), Flexion Therapeutics (FLXN), Iovance Biotherapeutics (IOVA), Marker Therapeutics (MRKR), Teva Pharmaceutical Industries (TEVA), Viking Therapeutics (VKTX), Verona Pharma (VRNA) and Adaptimmune Therapeutics (ADAP).

When did Sol-Gel Technologies IPO?

(SLGL) raised $60 million in an initial public offering (IPO) on Thursday, February 1st 2018. The company issued 5,000,000 shares at a price of $11.00-$13.00 per share. Jefferies and BMO Capital Markets acted as the underwriters for the IPO and JMP Securities and Raymond James were co-managers.

What is Sol-Gel Technologies' stock symbol?

Sol-Gel Technologies trades on the NASDAQ under the ticker symbol "SLGL."

How do I buy shares of Sol-Gel Technologies?

Shares of SLGL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sol-Gel Technologies' stock price today?

One share of SLGL stock can currently be purchased for approximately $14.70.

How much money does Sol-Gel Technologies make?

Sol-Gel Technologies has a market capitalization of $299.73 million and generates $22.90 million in revenue each year. The company earns $-24,610,000.00 in net income (profit) each year or ($1.26) on an earnings per share basis.

How many employees does Sol-Gel Technologies have?

Sol-Gel Technologies employs 65 workers across the globe.

What is Sol-Gel Technologies' official website?

The official website for Sol-Gel Technologies is www.sol-gel.com.

Where are Sol-Gel Technologies' headquarters?

Sol-Gel Technologies is headquartered at 7 GOLDA MEIR ST. WEIZMANN SCIENCE PARK, NESS ZIONA L3, 7403648.

How can I contact Sol-Gel Technologies?

Sol-Gel Technologies' mailing address is 7 GOLDA MEIR ST. WEIZMANN SCIENCE PARK, NESS ZIONA L3, 7403648. The company can be reached via phone at 972-8931-3429 or via email at [email protected]

This page was last updated on 4/16/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here